5-Hydroxytryptamine 1F Receptor Agonist Lasmiditan Differentially Regulates Successful Repair and Failed Repair Genes in a Mouse Model of Acute Kidney Injury.
Journal
ACS pharmacology & translational science
ISSN: 2575-9108
Titre abrégé: ACS Pharmacol Transl Sci
Pays: United States
ID NLM: 101721411
Informations de publication
Date de publication:
11 Oct 2024
11 Oct 2024
Historique:
received:
26
04
2024
revised:
28
08
2024
accepted:
16
09
2024
pmc-release:
24
09
2025
medline:
17
10
2024
pubmed:
17
10
2024
entrez:
17
10
2024
Statut:
epublish
Résumé
Increasing evidence substantiates the role of mitochondrial dysfunction, inflammation, fibrosis, and cell senescence in the onset and progression of acute kidney injury (AKI) to chronic kidney disease . The underlying governing cellular and transcriptional events, however, are not fully understood. Recently, the key factors that regulate successful and failed repair states in the proximal tubule have been identified at a single-cell resolution following bilateral ischemia-reperfusion (I/R) in a mouse model of AKI. Previously, our group showed that treatment with the FDA-approved selective 5-hydroxytryptamine receptor 1F agonist lasmiditan following AKI induces mitochondrial biogenesis , restores renal mitochondrial function, and increases renal and vascular recovery
Identifiants
pubmed: 39416968
doi: 10.1021/acsptsci.4c00246
pmc: PMC11475317
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3045-3055Informations de copyright
© 2024 American Chemical Society.
Déclaration de conflit d'intérêts
The authors declare no competing financial interest.